Myelodysplastic Syndrome Related to Successful Treatment With 177 Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38769640.
- Also identified by DOI 10.1097/RLU.0000000000005251.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
177 Lu-vipivotide tetraxetan ( 177 Lu-PSMA-617/LuPSMA) received recent EMA approval for metastatic castration-resistant prostate cancer, with promising data for earlier stages. Secondary myeloid neoplasm following exposure to DNA-damaging therapy (therapy-related myelodysplastic syndrome [MDS]) is a rare severe complication of 177 Lu-oxodotreotide. We present a 77-year-old man, with synchronous liver, bone, and lymph node metastatic prostate cancer, having developed a low-risk MDS with SF3B1 mutation, 1 month after the sixth administration of LuPSMA. Although on partial metabolic and biological response with PSA nadir at 7 months after therapy, life quality was significantly altered by MDS.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Myelodysplastic Syndromes
- Neoplasm Metastasis